Sanofi Says Sutimlimab Meets Endpoint in Phase 3 Trial
21 Novembre 2019 - 4:25PM
Dow Jones News
By Michael Dabaie
Sanofi (SNY) said sutimlimab met its primary efficacy endpoint
in a Phase 3 trial for patients with cold agglutinin disease.
CAD is a severe and chronic rare blood disorder in which the
immune system mistakenly attacks a person's own healthy red blood
cells. There are currently no approved treatments, Sanofi said.
A total of 24 patients were enrolled; two withdrew from the
study for non-drug related reasons. All 22 patients that completed
Part A of the study have enrolled in an ongoing long-term follow-up
study.
The primary efficacy outcome was response rate based on a
composite of an increase in hemoglobin from baseline or reaching a
hemoglobin level at treatment assessment endpoint and the absence
of transfusions between weeks 5 to 26.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 21, 2019 10:10 ET (15:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024